Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00836355 · ClinicalTrials.gov registry record · NA
Enoxaparin and/or Minocycline in Acute Stroke
A NA study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT00836355 is a NA study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 6 participants.
The verdict
NCT00836355, a NA study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate whether enoxaparin, minocycline, or both medications in combination may help in recovery from acute stroke. Enoxaparin (brand name Lovenox®) is a medication approved for use in humans to prevent and to treat blood clots in deep veins in certain specific medical situations. Minocycline (brand name Minocin®) is a tetracycline antibiotic approved to treat a number of bacterial infections in humans. The investigators are studying these medications in acute human stroke because they have each been separately shown to reduce the amount of injured brain tissue in rats made to have acute ischemic stroke experimentally. In a human trial comparing minocycline with placebo (a sugar pill) acute ischemic stroke patients who took minocycline had better recovery after 1 week, 1 month and 3 months than patients who took placebo.
Interventions
- DRUG Enoxaparin
- DRUG Minocycline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2009-04 |
| Est. Completion | 2010-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00836355
The ClinicalTrials.gov registry entry for NCT00836355 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Enoxaparin is the first listed.
NCT00836355 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00836355 about?
NCT00836355 is a clinical study titled "Enoxaparin and/or Minocycline in Acute Stroke". The purpose of this study is to investigate whether enoxaparin, minocycline, or both medications in combination may help in recovery from acute stroke. Enoxaparin (brand name Lovenox®) is a medication approved for use in humans to prevent and to treat blood clots in deep veins in certain specific m...
What is the current status of trial NCT00836355?
This trial is currently terminated. It is a NA study. The enrollment target is 6 participants. The study started on 2009-04. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00836355?
The interventions under investigation include: Enoxaparin (DRUG), Minocycline (DRUG).
Who is sponsoring clinical trial NCT00836355?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.